PDS Biotechnology Corporation

145 articles with PDS Biotechnology Corporation

• PDS Biotech Announces Preclinical Data for PDS0203, a T-Cell Activating Recombinant Protein Vaccine Against COVID-19

  7/27/2020

  Versamune-CoV-2 (PDS0203) generated high levels of robust, long-lasting CD8 (killer) T-cell responses and potent neutralizing antibody responses within 14 days of vaccination

• PDS Biotech Collaborator Granted NIAID Award to Accelerate Development of Versamune®-Based Universal Influenza Vaccine

  7/14/2020

  PDS Biotech ramps up third infectious disease vaccine program, PDS0202 for influenza, following PDS0201 for tuberculosis and PDS0203 for COVID-19

• PDS Biotech Announces Publication of Preclinical Results of PDS0101 Combination by the National Cancer Institute in the Journal for ImmunoTherapy of CancerNCI-led Phase 2 clinical trial of this reported combination was initiated in June 2020

  6/22/2020

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® T-cell activating technology, today announced the publication of data generated by the National Cancer Institute (NCI) based on preclinical studies of PDS Biotech’s lead clinical program, PDS0101, in combination with two other investigational an

• PDS Biotechnology and Farmacore Biotechnology Announce Co-Development of PDS0204 COVID-19 Vaccine

  6/17/2020

  Brazilian government to provide initial funding support to progress development of Versamune ® -based vaccine to prevent COVID-19 infection FLORHAM PARK, N.J., June 17, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® T-cell activating technology, today announced a co-development agreement with Farmacore Biotechnology fo

• PDS Biotech Announces Initiation of Phase 2 Trial of PDS0101 Led by the National Cancer Institute

  6/15/2020

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® T-cell activating technology, today announced that the first patient has been dosed in the National Cancer Institute’s (NCI) Phase 2 clinical study of PDS0101 in the treatment of advanced human papillomavirus (HPV) associated cancers. This clini

• PDS Biotech Announces Clinical Trial of Its Lead Immunotherapy Product, PDS0101, in Combination with Chemoradiotherapy in Advanced Cervical Cancer

  6/4/2020

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced a Phase 2 clinical trial to evaluate its lead immunotherapy product, PDS0101,

• PDS Biotechnology to Present at the 2020 Virtual Investor Summit

  6/2/2020

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® T-cell activating technology, today announced that Dr. Frank Bedu-Addo, President and Chief Executive Officer, is scheduled to present  at the 2020 Virtual Investor Summit being held on June 9-12, 2020. Details of the presentation are as follo

• PDS Biotechnology Reports Financial Results for the First Quarter 2020 and Provides Business Update

  5/13/2020

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced its financial results for the first quarter ended March 31, 2020 and provided a business update. First Quarter 2020 and Recent Business Highlights Initiated novel vaccine development programs for

• PDS Biotechnology Announces Publication at American Society of Clinical Oncology (ASCO) 2020

  5/13/2020

  PDS Biotechnology Corporation announced the publication of its abstract on preclinical studies of PDS0102 at the American Society of Clinical Oncology Virtual Scientific Program being held May 29-31, 2020.

• PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2020 Financial Results

  5/4/2020

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced that the Company will release financial results for the first quarter ended March 31, 2020 on Wednesday, May 13, 2020, before the market opens. Following the release, Dr. Frank Bedu-Addo, Chief Executiv

• PDS Biotechnology Expands CRADA with the National Cancer Institute to Include Second Versamune®-Based Anti-Cancer Product

  4/29/2020

  NCI to study PDS0103, in addition to planned Phase 2 clinical evaluation of PDS0101 in combination with other therapeutic agents

• PDS Biotechnology Initiates Novel Vaccine Development Programs For COVID-19 and Universal Influenza; Delay of PDS0101 VERSATILE-002 trial

  4/16/2020

  Expanded infectious disease program to address current and potential pandemics builds on existing tuberculosis collaboration Initiation of Phase 2 VERSATILE-002 trial for PDS0101 in advanced/metastatic head and neck cancer delayed due to global COVID-19 pandemic

• 

  Biopharma Update on the Novel Coronavirus: April 16

  4/16/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 16, 2020.

• PDS Biotechnology Appoints Dr. Ilian Iliev to Board of Directors

  4/9/2020

  PDS Biotechnology Corporation today announced that it has appointed Ilian Iliev, Ph.D. to its Board of Directors. “We are very pleased to welcome Dr. Iliev to the Board of Directors. He brings a wealth of experience to PDS Biotech as a recognized entrepreneur and venture capital

• PDS Biotechnology Reports Full Year 2019 Financial Results and Provides Business Update

  3/27/2020

  PDS Biotechnology Corporation (“PDS Biotechnology”) (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on T-cell activating technology called Versamune® today announced its financial results for the full year ended December 31, 2019 and provided a business update.

• PDS Biotechnology Announces Resignation of Andrew Saik as CFO

  3/23/2020

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced that Andrew Saik has resigned as the Company’s Chief Financial Officer (CFO) and a director of the board to pursue other professional opportunities, effective immediately.

• PDS Biotechnology Expands Patent Portfolio for its Novel Versamune® PlatformGranted Composition of Matter Patent for Versamune® Platform by the United States Patent and Trademark Office

  3/5/2020

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced that it has been granted U.S. Patent No. 15/702,063 titled “Stimulation of an Immune Response by Enantiomers of Cationic Lipids” by the United States Patent and Trademark Office (USPTO).

• PDS Biotechnology Announces Commencement of Work Under a Pre-Clinical Collaboration with Farmacore Biotechnology for Tuberculosis

  2/27/2020

  PDS Biotechnology Corporation announced commencement of work under an Amended and Restated Material Transfer Agreement with Farmacore Biotechnology, experts in infectious diseases, to develop a novel tuberculosis immunotherapy based on Farmacore’s proprietary TB antigens and PDS Bio’s Versamune® platform technology.

• PDS Biotechnology Appoints Kamil Ali-Jackson, Esq. to Board of Directors

  2/24/2020

  PRINCETON, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced that it has appointed Kamil Ali-Jackson, Esq. to its Board of Directors. Ms. Ali-Jackson will be a member of the Board’s audit committee. “We are very pleased to welcome Kamil to the Board of Directors and look forward to her insights a

• PDS Biotechnology to Present at Noble Capital Markets' 16th Annual Small & Microcap Investor Conference

  2/17/2020

  PRINCETON, N.J., Feb. 17, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced that Dr. Frank Bedu-Addo, President and Chief Executive Officer and Dr. Lauren Wood, Chief Medical Officer are scheduled to participate in Noble Capital Markets' 16 th Annual Small & Microcap Investor Conference being held on Februar